dorsaVi (ASX:DVL) - CEO, Dr Andrew Ronchi
CEO, Dr Andrew Ronchi
Source: North Road Physiotherapy
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • dorsaVi’s (DVL) share price has skyrocketed 900 per cent after becoming a strategic partner of QBE Australia.
  • Under the new commercial collab, DVL will provide QBE customers with wearable devices to help reduce injury claims
  • dorsaVi’s on-body sensors will be used in real-time, monitoring and measuring movements, muscle activity and movement risks
  • As a result, Australia’s second-largest global insurer has pre-allocated $250,000 over an initial 12 month period to provide its customer with access to dorsaVi’s technology
  • Company shares are still up a considerable 462 per cent on the market today, trading for 7.3 cents each

dorsaVi’s (DVL) share price has skyrocketed 900 per cent after becoming a strategic partner of QBE Australia.

Under the new commercial collab, DVL will provide QBE customers with wearable devices to help reduce injury claims.

As a result, Australia’s second-largest global insurer has pre-allocated $250,000 over an initial 12 month period to provide its customer with access to dorsaVi’s technology.

QBE Australia’s General Manager for People Risk, Rob Kosova, said over the past two years, the company has been looking at ways to reduce the risk of injury at work.

“New technologies offer great promise for taking a proactive role in making workplaces safer and we’re excited to be working with dorsaVi’s technology to achieve this,” he said.

“The consequences of workplace injuries can be significant and sometimes, sadly, long-lasting. SafeWork Australia puts the total cost of workplace injury and disease at around four per cent of gross domestic product (GDP) over one-third of these are due to body stressing or manual handling,” he added.

Via the wearable tech, dorsaVi’s on-body sensors will be used in real-time and will monitor and measure movements, muscle activity and movement risk.

dorsaVi CEO Dr Andrew Ronchi is excited to partner with QBE.

“One of the goals for insurers is to be able to pro-actively manage risk and have remote visibility on where their potential risks are, allowing insurers and corporate groups to mitigate these risks and prove solutions before they are implemented,” he said.

“We look forward to adding value to the QBE Australia business and to their clients’ businesses,” he added.

Company shares are still up a considerable 462 per cent on the market today, trading for 7.3 cents each at 12:57 pm AEST.

DVL by the numbers
More From The Market Herald
Memphasys (ASX:MEM) - Managing Director & CEO, Alison Coutts

" Memphasys (ASX:MEM) launches $3.36m capital raising for Felix System commercialisation

Reproduction biotechnology and bio-separations company Memphasys (ASX:MEM) has launched a $3.36 million capital raising.
The Market Herald Video

" PharmAust (ASX:PAA) sees “significant progress” in dog cancer trials

Biotech company PharmAust (ASX:PAA) has reported "significant progress" on its canine cancer.

" MGC Pharmaceuticals (ASX:MXC) receives $1m ArtemiC order

MGC Pharmaceuticals (ASX:MXC) has received a US$1 million (A$1.43 million) order for its anti-inflammatory product, ArtemiC.
The Market Herald Video

" Emyria (ASX:EMD) launches phase 3 EMD-RX5 trial

Emyria (ASX:EMD) has launched its phase three clinical trial of its ultra-pure CBD candidate.